Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAston Martin Lagonda Regulatory News (AML)

Share Price Information for Aston Martin Lagonda (AML)

Share Price is delayed by 15 minutes
Get Live Data
41.12    -1.44 (-3.38%)
Bid:
41.06
Ask:
43.48
Spread: 2.42 (5.894%)
Market Cap: £416.42m
AML Live PriceLast checked at - London Stock Exchange

Intraday Aston Martin Lagonda Share Chart

Stabilisation Notice

3 Oct 2018 07:00

RNS Number : 7670C
Goldman Sachs International
03 October 2018
 

Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful.

Aston Martin Lagonda Global Holdings plc

Stabilisation Notice

03 October 2018

Goldman Sachs International hereby gives notice that the entity undertaking stabilisation (the "Stabilisation Manager" named below and its affiliates) may stabilise the offer of the following securities in accordance with Regulation (EU) No 596/2014 (Market Abuse Regulation) and Commission Delegated Regulation (EU) 2016/1052. Stabilisation transactions aim at supporting the market price of the Securities during the Stabilisation Period. Stabilisation may not necessarily occur and it may cease at any time.

The securities:

Issuer:

Aston Martin Lagonda Global Holdings plc

Securities:

Ordinary registered shares ("ORDs" or "Ordinary Shares") of the Issuer (ISIN: GB00BFXZC448)

Offering size:

 57,000,723 Ordinary Shares (excluding the over-allotment option)

Offer Price:

GBP19.00

Stabilisation:

Stabilisation Manager (and central point within the meaning of Commission Delegated Regulation (EU) 2016/1052):

Goldman Sachs International, Peterborough Court, 133 Fleet Street, London EC4A 2BB

Contact: John Bentinck; telephone: +44 (0)20 7774 3408

Beginning of the Stabilisation Period:

03 October 2018

Stabilisation Period to end no later than:

02 November 2018

Trading venue where stabilisation may be undertaken:

London Stock Exchange ("LSE"), BATS, Chi-X

Over-allotment & Greenshoe Option:

Terms:

In connection with the offering (the "Offer"), the Stabilisation Manager, or any of its agents, may (but will be under no obligation to), to the extent permitted by applicable law, over-allot Ordinary Shares sold in the Offer (the "Offer Shares") or effect other stabilisation transactions with a view to supporting the market price of the Offer Shares at a level higher than that which might otherwise prevail in the open market pursuant to an over-allotment option granted to it in connection with the Offer (the "Over-allotment Option"). The Stabilisation Manager is not required to enter into such transactions and such transactions may be effected on any securities market, over-the-counter market, stock exchange or otherwise and may be undertaken at any time during the period commencing on the date of the commencement of conditional dealings in the Offer Shares on the LSE and ending no later than 30 calendar days thereafter. There will be no obligation on the Stabilisation Manager or any of its agents to effect stabilising transactions and there is no assurance that stabilising transactions will be undertaken. Such stabilisation, if commenced, may be discontinued at any time without prior notice. In no event will measures be taken to stabilise the market price of the Offer Shares above £19.00 per Offer Share. Except as required by law or regulation, neither the Stabilisation Manager nor any of its agents intends to disclose the extent of any over-allotments made and/or stabilisation transactions conducted in relation to the Offer.

In connection with the Offer, the Stabilisation Manager may, for stabilisation purposes, over-allot Offer Shares up to a maximum of 10% of the total number of Offer Shares comprised in the Offer.

The Over-allotment Option is exercisable in whole or in part, upon notice by the Stabilisation Manager, at any time on or before the 30th calendar day after the commencement of conditional dealings in the Offer Shares on the LSE. Any Over-allotment Shares made available pursuant to the Over-allotment Option will rank pari passu in all respects with all other Ordinary Shares, including for all dividends and other distributions declared, made or paid on the Ordinary Shares, will be purchased on the same terms and conditions as the Offer Shares being issued or sold in the Offer and will form a single class for all purposes with the other Ordinary Shares.

Number of shares covered by Over-allotment Option:

5,700,072 Ordinary Shares

Duration:

This option may be executed at any time during the Stabilisation Period.

 

 

 

Disclaimer

 

In connection with the offer of the above securities, the Stabilisation Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilisation Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time.

 

This announcement is for information only and does not constitute an offer or invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities or investment advice in any jurisdiction in which such an offer or solicitation is unlawful, including without limitation, the United States, Australia, Canada, or Japan. Any failure to comply with these restrictions may constitute a violation of the securities laws of such jurisdictions.

 

This announcement and the information contained herein, is not an offer of securities for sale in, and is not for transmission to or publication, distribution or release, directly or indirectly, in the United States of America (including its territories and possessions, any state of the United States of America and the District of Columbia) (the "United States"). The securities being offered have not been and will not be registered under the US Securities Act of 1933, as amended (the "Securities Act"), or under any applicable securities laws of any state or other jurisdiction of the United States and may not be offered, sold, resold, transferred or delivered, directly or indirectly, in the United States unless registered under the Securities Act or pursuant to an exemption from, or in a transaction not subject to, such registration requirements and in accordance with any applicable securities laws of any state or other jurisdiction of the United States. No public offering of the securities discussed herein is being made in the United States.

 

This announcement is directed only at: (A) persons in member states of the European Economic Area (the "EEA") who are "qualified investors" within the meaning of Article 2(1)(e) of the EU Prospectus Directive (Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, to the extent implemented in the relevant member state of the EEA) and includes any relevant implementing measure in each relevant member state of the EEA) (the "Qualified Investors"); (B) in the United Kingdom, Qualified Investors who are persons who (i) have professional experience in matters relating to investments and who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order"); or (ii) are high net worth entities falling within Article 49 of the Order; or (iii) are persons to whom it may otherwise be lawfully communicated. If you are not a person to whom this announcement is directed as set out in (A) and (B) above, you will not be eligible to participate in the offering, and you should not act upon, or rely on, this announcement.

 

END

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STAUGGGCUUPRPUP
Date   Source Headline
4th Jun 20267:00 amRNSIssue of equity to satisfy share awards
15th May 20267:00 amRNSIssue of equity to satisfy employee share awards
6th May 202612:51 pmRNSVoting results of AGM 2026
29th Apr 20267:00 amRNSQ1 results for three months ended 31 March 2026
25th Mar 20269:53 amRNSAnnual Financial Report
9th Mar 202612:12 pmRNSResult of Meeting
25th Feb 20267:00 amRNSPreliminary Results FY2025
20th Feb 20267:00 amRNSNotice of GM and FY 2025 Trading Update
29th Oct 20257:00 amRNSQ3 results for the quarter ended 30 September 2025
6th Oct 20257:00 amRNSQ3 2025 Trading Update and revised outlook
10th Sep 202511:33 amRNSDirector/PDMR Shareholding
5th Sep 20257:00 amRNSIssue of equity to satisfy employee share awards
30th Jul 20257:00 amRNSInterim results
28th Jul 20254:33 pmRNSDirectorate Change
27th May 202510:13 amRNSDirector/PDMR Shareholding
27th May 202510:12 amRNSDirector/PDMR Shareholding
15th May 202510:38 amRNSHolding(s) in Company
13th May 20255:26 pmRNSHolding(s) in Company
13th May 202510:33 amRNSDirector/PDMR Shareholding
13th May 202510:31 amRNSDirector/PDMR Shareholding
13th May 202510:26 amRNSDirector/PDMR Shareholding
12th May 20255:53 pmRNSHolding(s) in Company
12th May 20251:13 pmRNSHolding(s) in Company
12th May 202512:52 pmRNSHolding(s) in Company
7th May 20252:45 pmRNSDirector/PDMR Shareholding
7th May 20251:15 pmRNSResult of General Meeting and issue of equity
7th May 20251:07 pmRNSVoting Result of AGM
30th Apr 20257:00 amRNS1st Quarter Results
17th Apr 20258:57 amRNSNotice of General Meeting
16th Apr 20253:20 pmRNSDirector Declaration
31st Mar 20255:11 pmRNSStatement regarding media comments
31st Mar 20257:00 amRNSProposed investment by Yew Tree Consortium
26th Mar 20259:24 amRNSAnnual Financial Report
26th Feb 20257:00 amRNSPreliminary results year ended 31 December 2024
25th Feb 202510:00 amRNSIndependent Non-executive Director appointment
7th Feb 20255:29 pmRNSHolding(s) in Company
13th Dec 20249:00 amRNSDirectorate Change
4th Dec 20244:00 pmRNSHolding(s) in Company
29th Nov 20244:15 pmRNSHolding(s) in Company
29th Nov 20241:01 pmRNSHolding(s) in Company
29th Nov 202412:46 pmRNSDirector/PDMR Shareholding Replacement
29th Nov 202412:18 pmRNSDirector/PDMR Shareholding
29th Nov 202412:17 pmRNSDirector/PDMR Shareholding
29th Nov 202412:11 pmRNSDirector/PDMR Shareholding
27th Nov 20247:00 amRNSResult of Equity Issue
26th Nov 20245:06 pmRNSIssue of Equity
26th Nov 20244:58 pmRNSIssue of Equity
6th Nov 202410:37 amRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNS3rd Quarter Results
30th Sep 20247:00 amRNSTrading Update and adjustment to FY 2024 guidance

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.